Plasma-derived Medicinal Products Market size was valued at USD 25 Billion in 2022 and is projected to reach USD 40 Billion by 2030, growing at a CAGR of 6.0% from 2024 to 2030.
The Plasma-derived Medicinal Products (PDMP) market has seen significant growth in recent years, driven by advances in medical science and increasing demand for therapeutic treatments derived from human plasma. Plasma-derived products are critical in treating a wide variety of conditions such as immune system disorders, coagulation disorders, and antibody deficiencies. These products are created by separating the components of plasma through a process called fractionation. The therapeutic potential of plasma-derived products is vast, spanning across numerous applications, including emergency care, epidemic disease management, and the treatment of chronic immune and coagulation disorders.
Download Full PDF Sample Copy of Plasma-derived Medicinal Products Market Report @ https://www.verifiedmarketreports.com/download-sample/?rid=362106&utm_source=GSJ&utm_medium=207
Emergency care remains one of the most critical areas of application for plasma-derived medicinal products. In emergency situations, particularly in cases of trauma, burns, and critical illnesses, these products are vital in stabilizing patients and preventing life-threatening complications. Products like intravenous immunoglobulin (IVIg) and clotting factor concentrates are used extensively to manage acute medical conditions. For example, plasma-derived clotting factors are essential in managing severe bleeding episodes in patients with hemophilia, while immunoglobulins play a pivotal role in boosting immune functions in cases of sudden, severe infections. The ability of plasma-derived products to act quickly in life-threatening situations makes them indispensable in emergency medicine.
The demand for plasma-derived medicinal products in emergency care is further fueled by the increasing number of trauma cases globally, including those arising from accidents, natural disasters, and military conflicts. As healthcare systems strive to improve their emergency response capabilities, plasma-derived products provide critical support in the form of immediate and effective treatment options. As a result, this segment is expected to experience steady growth over the coming years. Additionally, the expansion of emergency healthcare infrastructure, particularly in developing regions, is likely to enhance access to these life-saving therapies.
The outbreak of epidemic diseases has led to an increased reliance on plasma-derived medicinal products for effective management and treatment. These products are crucial in the treatment of diseases such as COVID-19, where convalescent plasma therapy has been explored as a potential therapeutic option. Plasma from recovered patients contains antibodies that can help neutralize the virus in infected individuals, offering a potential treatment method for emerging viral diseases. Additionally, immunoglobulin therapies are used for a variety of infectious diseases, providing passive immunity and reducing the severity of infections in immunocompromised patients. Plasma-derived therapies offer an important line of defense, particularly in situations where no specific antiviral drugs are available.
The growing prevalence of epidemic diseases, especially those caused by novel pathogens, has created both challenges and opportunities in the plasma-derived medicinal products market. Governments and healthcare organizations worldwide are recognizing the importance of maintaining a reliable supply of plasma for therapeutic use during epidemics. Additionally, advances in plasma collection technologies and better logistical frameworks for distribution are expected to bolster the market for epidemic disease management. As the world faces increasingly unpredictable health crises, the demand for plasma-derived therapies in epidemic control and prevention is likely to rise.
Immune system disorders, such as autoimmune diseases and immunodeficiencies, are another key area of application for plasma-derived medicinal products. Immunoglobulins (IgG) are among the most commonly used plasma-derived therapies in the treatment of these disorders. Immunoglobulin replacement therapy helps patients with primary or secondary immunodeficiencies by boosting their immune response. Conditions such as primary immunodeficiency diseases (PIDDs) and certain autoimmune disorders, including chronic inflammatory demyelinating polyneuropathy (CIDP) and myasthenia gravis, are treated with intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg), both of which help modulate immune function and alleviate symptoms.
The increasing prevalence of immune system disorders, particularly in aging populations and those with genetic predispositions, is expected to drive significant demand for plasma-derived therapies. These treatments have proven to be effective in not only restoring immune function but also in managing autoimmune diseases by regulating abnormal immune responses. Furthermore, ongoing research into optimizing and improving the efficacy of immunoglobulin therapies is likely to contribute to market expansion. As awareness of immune system disorders grows, the need for specialized plasma-derived products will continue to rise, creating opportunities for new product developments and market entrants.
Antibody deficiency disorders are characterized by the body’s inability to produce sufficient antibodies, leading to recurrent and severe infections. Plasma-derived medicinal products, particularly immunoglobulin therapies, are the cornerstone of treatment for patients with antibody deficiencies. These therapies, which are derived from the pooled plasma of healthy donors, provide the missing antibodies that are essential for fighting off infections. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are commonly used to manage these conditions and help prevent life-threatening infections in patients with conditions such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA).
The market for plasma-derived products used to treat antibody deficiencies is expected to grow as awareness of these conditions increases. Advances in diagnostic technologies are enabling earlier detection of antibody deficiencies, which leads to more timely treatment and better patient outcomes. Additionally, as more individuals are diagnosed and treated for antibody deficiency disorders, the demand for plasma-derived immunoglobulins is likely to increase. The availability of new formulations and more convenient administration options (such as SCIG, which allows for home therapy) is also expected to drive market growth in this segment.
Coagulation disorders, such as hemophilia and von Willebrand disease, are characterized by the blood’s inability to clot properly, leading to excessive bleeding. Plasma-derived clotting factors, including Factor VIII and Factor IX, are crucial in the treatment of these disorders. These products are used to replace the missing or deficient clotting factors in the blood, helping to prevent or control bleeding episodes. Patients with hemophilia, for instance, require regular infusions of clotting factor concentrates to maintain a stable level of coagulation and avoid life-threatening bleeding episodes. The development of recombinant clotting factor therapies has further expanded treatment options, but plasma-derived products remain essential for managing severe cases of these disorders.
The growing recognition of coagulation disorders, coupled with ongoing advances in plasma fractionation techniques, is driving demand for plasma-derived clotting factor concentrates. The increasing prevalence of bleeding disorders, especially hemophilia, is also contributing to market growth. As treatment options improve and access to plasma-derived therapies expands in both developed and emerging markets, this segment is expected to continue its upward trajectory. The ability to provide more personalized and targeted therapies for individuals with coagulation disorders, particularly with advancements in gene therapy and more effective clotting factors, represents a significant opportunity for the market.
The "Others" category in the plasma-derived medicinal products market encompasses a variety of therapeutic areas not specifically covered in the aforementioned segments. These may include treatments for burns, shock, chronic diseases, and certain rare conditions. Plasma-derived albumin is one such product used for patients suffering from liver diseases, burns, or shock, where it helps to restore blood volume and maintain proper fluid balance. Furthermore, clotting factors and immunoglobulins may be used off-label for conditions such as autoimmune diseases, cancer therapy, or neurodegenerative disorders, although these uses are less common. This diverse range of applications broadens the overall potential of plasma-derived medicinal products and contributes to the growth of the market.
The "Others" segment also includes emerging therapies and novel indications that continue to be explored in clinical trials. As the science behind plasma fractionation and therapeutic uses of plasma evolves, new applications may arise, further expanding the range of treatments available to patients. Additionally, growing recognition of the therapeutic benefits of plasma-derived products in various medical fields could stimulate greater investment in research and development, leading to the discovery of new and innovative uses for plasma-derived medicines.
Several key trends are currently shaping the Plasma-derived Medicinal Products market. One significant trend is the increasing adoption of home-based therapies, particularly for immunoglobulin and coagulation factor treatments. Advances in subcutaneous administration methods have made it easier for patients to manage their conditions outside of healthcare facilities, providing greater convenience and improving quality of life. Additionally, the trend towards personalized medicine, where treatments are tailored to the specific needs of individual patients, is expected to drive innovation in plasma-derived therapies.
Another trend gaining momentum is the growing focus on plasma donation and collection. As the demand for plasma-derived products continues to rise, there is an increasing emphasis on building robust donor networks and improving plasma collection technologies. This is crucial to ensuring a steady and reliable supply of raw material for fractionation. Additionally, the use of recombinant technologies alongside plasma-derived products is expanding, with hybrid therapies that combine the benefits of both approaches showing promising results in clinical trials.
The Plasma-derived Medicinal Products market presents significant growth opportunities, particularly in emerging markets where healthcare infrastructure is expanding. As more people in developing regions gain access to healthcare, the demand for plasma-derived therapies is expected to increase, particularly for the treatment of immune system disorders and coagulation disorders. Additionally, there is growing interest in developing new plasma-derived products for rare and orphan diseases, where existing treatments may be limited.
Another key opportunity lies in technological advancements in plasma fractionation and purification techniques. By improving the efficiency and yield of plasma-derived products
Top Plasma-derived Medicinal Products Market Companies
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
Shanghai RAAS
China Biologic Products
Hualan Biological Engineering Inc.
Beijing Tiantan Biological Products Corp
Pacific Shuanglin
Boya Bio-Pharmaceutical
Paisi Feike Biology Pharmacy Co.
Ltd.
Xinjiang Deyuan Bioengineering
Sichuan Yuanda Shuyang Pharmaceutical Co.
Ltd.
Shenzhen Weiguang
Shanxi Kangbao
Nanyue Biopharming Corporation Ltd
Regional Analysis of Plasma-derived Medicinal Products Market
North America (United States, Canada, and Mexico, etc.)
Asia-Pacific (China, India, Japan, South Korea, and Australia, etc.)
Europe (Germany, United Kingdom, France, Italy, and Spain, etc.)
Latin America (Brazil, Argentina, and Colombia, etc.)
Middle East & Africa (Saudi Arabia, UAE, South Africa, and Egypt, etc.)
For More Information or Query, Visit @
Plasma-derived Medicinal Products Market Insights Size And Forecast